Why did OSX.AX stock drop so sharply on 27 Jan 2026?

The fall reflected heavy volume, thin liquidity, and negative fundamentals. OSX.AX has EPS **-0.04** and small market cap **~A$5.65M**. Large sell orders amplified the move in a low-float healthcare stock with no single public catalyst reported.

What is Meyka AI's forecast for OSX.AX stock?

Meyka AI's forecast model projects **A$0.010** monthly and **A$0.090** quarterly. Versus the current price **A$0.015**, that implies **-33.33%** monthly downside and **+500.00%** quarterly upside. Forecasts are model-based and not guarantees.

What are the main valuation metrics for OSX.AX stock?

Key metrics: EPS **-0.04**, PE **-0.50**, price-to-sales **1.95**, price-to-book **-8.64**, cash per share **A$0.00987**. These figures show negative earnings and a fragile balance sheet relative to sector peers.

What catalysts should investors watch for OSX.AX stock?

Watch the earnings announcement on **26 Feb 2026**, regulatory approvals, partnership updates and daily liquidity. Material positive news or improved cash flow could trigger recovery in this small-cap healthcare name.

AU Stocks

OSX.AX falls 42% to A$0.015 on ASX 27 Jan 2026: liquidity and forecast risks

ByDanny Kontos January 27, 2026January 27, 2026

OSX.AX stock plunged 42.31% to A$0.015 at the close of trading on 27 Jan 2026 on the ASX. The move came on heavy turnover of 34,551,063 shares and pushed the penny stock far below its 50-day average. Osteopore Limited (OSX.AX) now trades with a market capitalisation near A$5.65M. We summarise the drivers, key ratios, Meyka AI grade and the model forecast that frames short-term downside and selective upside scenarios